{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:49:27Z","timestamp":1765039767956,"version":"3.41.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Municipal Health Commission Scientific Research Projects","award":["20214Y0186"],"award-info":[{"award-number":["20214Y0186"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02281-1","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T09:21:21Z","timestamp":1750497681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and clinical relavance of germline mutations in Chinese patients with pancreatic cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Yu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiejie","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2281_CR1","doi-asserted-by":"crossref","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R et al. Cancer incidence and mortality in china, 2022. J Natl Cancer Cent. 2024;4(1).","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"2281_CR2","doi-asserted-by":"crossref","unstructured":"Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30).","DOI":"10.1200\/JCO.2017.72.3502"},{"key":"2281_CR3","doi-asserted-by":"crossref","unstructured":"Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst. 2018;110(10).","DOI":"10.1093\/jnci\/djy024"},{"key":"2281_CR4","doi-asserted-by":"crossref","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. In: JAMA - Journal of the American Medical Association; 2018.","DOI":"10.1001\/jama.2018.6228"},{"key":"2281_CR5","doi-asserted-by":"crossref","unstructured":"Yin L, Wei J, Lu Z, Huang S, Gao H, Chen J et al. Prevalence of germline sequence variations among patients with pancreatic Cancer in China. JAMA Netw Open. 2022;5(2).","DOI":"10.1001\/jamanetworkopen.2021.48721"},{"key":"2281_CR6","doi-asserted-by":"crossref","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol. 2020;21(4).","DOI":"10.1016\/S1470-2045(20)30074-7"},{"key":"2281_CR7","doi-asserted-by":"crossref","unstructured":"Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA - J Am Med Association. 2017;318(9).","DOI":"10.1001\/jama.2017.11137"},{"key":"2281_CR8","unstructured":"Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z et al. NCCN Guidelines\u00ae Insights: Genetic\/Familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2024. J Natl Compr Canc Netw. 2023;21(10)."},{"key":"2281_CR9","doi-asserted-by":"crossref","unstructured":"Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O\u2019Reilly EM. An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: A review. 6, JAMA Oncol. 2020.","DOI":"10.1001\/jamaoncol.2019.5963"},{"key":"2281_CR10","doi-asserted-by":"crossref","unstructured":"Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Busset MDD et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer. JAMA Netw Open. 2024.","DOI":"10.1001\/jamanetworkopen.2023.50756"},{"key":"2281_CR11","doi-asserted-by":"crossref","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al. Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4).","DOI":"10.1056\/NEJMoa1903387"},{"key":"2281_CR12","doi-asserted-by":"crossref","unstructured":"Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncol. 2021;7(5).","DOI":"10.1001\/jamaoncol.2021.0006"},{"key":"2281_CR13","doi-asserted-by":"crossref","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, Teitelbaum U, Karasic TB, Schneider C et al. Phase II study of maintenance Rucaparib in patients with Platinum-Sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39(22).","DOI":"10.1200\/JCO.21.00003"},{"key":"2281_CR14","doi-asserted-by":"crossref","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21.","DOI":"10.1038\/s41575-023-00840-w"},{"key":"2281_CR15","doi-asserted-by":"crossref","unstructured":"Zhao Z, Li X, Wang F, Xu Y, Liu S, Han Q et al. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. Cancer Med. 2023;12(10).","DOI":"10.1002\/cam4.5871"},{"key":"2281_CR16","doi-asserted-by":"crossref","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for illumina sequence data. Bioinformatics. 2014;30(15).","DOI":"10.1093\/bioinformatics\/btu170"},{"key":"2281_CR17","doi-asserted-by":"crossref","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14).","DOI":"10.1093\/bioinformatics\/btp324"},{"key":"2281_CR18","doi-asserted-by":"crossref","unstructured":"Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, Mcewen R et al. VarDict: A novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11).","DOI":"10.1093\/nar\/gkw227"},{"key":"2281_CR19","unstructured":"Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing -- Free bayes -- Variant Calling -- Longranger. arXiv preprint arXiv:12073907. 2012."},{"key":"2281_CR20","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Sci. 2015;17(5).","DOI":"10.1038\/gim.2015.30"},{"key":"2281_CR21","doi-asserted-by":"crossref","unstructured":"Daly LE. Confidence limits made easy: interval Estimation using a substitution method. Am J Epidemiol. 1998;147(8).","DOI":"10.1093\/oxfordjournals.aje.a009523"},{"key":"2281_CR22","unstructured":"Bland JM. An Introduction to Medical Statistics, 3rd edition. Oxford University Press. 2000."},{"key":"2281_CR23","doi-asserted-by":"crossref","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809).","DOI":"10.1530\/ey.17.14.3"},{"key":"2281_CR24","doi-asserted-by":"crossref","unstructured":"Cao Y, Li L, Xu M, Feng Z, Sun X, Lu J et al. The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals. Cell Res. 2020;30(9).","DOI":"10.1038\/s41422-020-0322-9"},{"key":"2281_CR25","doi-asserted-by":"crossref","unstructured":"Hertzberg VS, Sahai H, Khurshid A. Statistics in epidemiology: methods, techniques, and applications. J Am Stat Assoc. 1997;92(439).","DOI":"10.2307\/2965601"},{"key":"2281_CR26","doi-asserted-by":"crossref","unstructured":"Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4).","DOI":"10.1038\/ng.788"},{"key":"2281_CR27","unstructured":"Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;(1)."},{"key":"2281_CR28","doi-asserted-by":"crossref","unstructured":"Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F et al. 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes. Eur J Hum Genet. 2022;30(4).","DOI":"10.1038\/s41431-021-01011-8"},{"key":"2281_CR29","doi-asserted-by":"crossref","unstructured":"Dbouk M, Katona BW, Brand RE, Chak A, Syngal S, Farrell JJ et al. The multicenter Cancer of pancreas screening study: impact on stage and survival. J Clin Oncol. 2022;4.","DOI":"10.1200\/JCO.22.00298"},{"key":"2281_CR30","doi-asserted-by":"crossref","unstructured":"Bird A. DNA methylation patterns and epigenetic memory. Vol. 16, Genes and Development. 2002.","DOI":"10.1101\/gad.947102"},{"key":"2281_CR31","doi-asserted-by":"crossref","unstructured":"Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de Novo methylation and mammalian development. Cell. 1999;99(3).","DOI":"10.1016\/S0092-8674(00)81656-6"},{"key":"2281_CR32","doi-asserted-by":"crossref","unstructured":"Zhang JJ, Zhu Y, Zhu Y, Wu JL, Liang WB, Zhu R et al. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2012;14(2).","DOI":"10.1007\/s12094-012-0770-x"},{"key":"2281_CR33","doi-asserted-by":"crossref","unstructured":"Jing W, Song N, Liu YP, Qu XJ, Qi YF, Li C et al. DNMT3A promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer. Cancer Manag Res. 2019;11.","DOI":"10.2147\/CMAR.S201610"},{"key":"2281_CR34","doi-asserted-by":"crossref","unstructured":"Jing W, Song N, Liu Y, Qu X, Hou K, Yang X et al. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells. Mol Med Rep. 2018;17(1).","DOI":"10.3892\/mmr.2017.7923"},{"key":"2281_CR35","doi-asserted-by":"crossref","unstructured":"Smith AM, LaValle TA, Shinawi M, Ramakrishnan SM, Abel HJ, Hill CA et al. Functional and epigenetic phenotypes of humans and mice with DNMT3A overgrowth syndrome. Nat Commun. 2021;12(1).","DOI":"10.1038\/s41467-021-24800-7"},{"key":"2281_CR36","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Beird HC, Estecio M, Hardikar S, Takahashi K, Bannon SA et al. Germline DNMT3A mutation in Familial acute myeloid leukaemia. Epigenetics. 2021;16(5).","DOI":"10.1080\/15592294.2020.1809871"},{"key":"2281_CR37","doi-asserted-by":"crossref","unstructured":"Mellid S, Coloma J, Calsina B, Monteagudo M, Rold\u00e1n-Romero JM, Santos M et al. Novel DNMT3A germline variant in a patient with multiple paragangliomas and papillary thyroid carcinoma. Cancers (Basel). 2020;12(11).","DOI":"10.3390\/cancers12113304"},{"key":"2281_CR38","doi-asserted-by":"crossref","unstructured":"Brown TJ, Yablonovitch A, Till JE, Yen J, Kiedrowski LA, Hood R et al. The clinical implications of reversions in patients with advanced pancreatic Cancer and pathogenic variants in BRCA1, BRCA2, or PALB2 after progression on Rucaparib. Clin Cancer Res. 2023;29(24).","DOI":"10.1158\/1078-0432.CCR-23-1467"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02281-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02281-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T09:21:31Z","timestamp":1750497691000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02281-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02281-1","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"300"}}